Effect of extended-release niacin on plasma lipoprotein(a) levels: A systematic review and meta-analysis of randomized placebo-controlled trials.

[1]  A. Sahebkar,et al.  Supplementation with coenzyme Q10 reduces plasma lipoprotein(a) concentrations but not other lipid indices: A systematic review and meta-analysis. , 2016, Pharmacological research.

[2]  A. Sahebkar,et al.  Impact of L-carnitine on plasma lipoprotein(a) concentrations: A systematic review and meta-analysis of randomized controlled trials , 2016, Scientific Reports.

[3]  E. Stein,et al.  Non-statin Treatments for Managing LDL Cholesterol and Their Outcomes. , 2015, Clinical therapeutics.

[4]  G. Watts,et al.  Effects of Extended-Release Niacin on the Postprandial Metabolism of Lp(a) and ApoB-100–Containing Lipoproteins in Statin-Treated Men With Type 2 Diabetes Mellitus , 2015, Arteriosclerosis, thrombosis, and vascular biology.

[5]  A. Sahebkar,et al.  Effect of statin therapy on paraoxonase-1 status: A systematic review and meta-analysis of 25 clinical trials. , 2015, Progress in lipid research.

[6]  A. Wen,et al.  Effect of niacin on lipids and glucose in patients with type 2 diabetes: A meta-analysis of randomized, controlled clinical trials. , 2015, Clinical nutrition.

[7]  Ž. Reiner.  Management of patients with familial hypercholesterolaemia , 2015, Nature Reviews Cardiology.

[8]  A. Sahebkar,et al.  Tibolone decreases Lipoprotein(a) levels in postmenopausal women: A systematic review and meta-analysis of 12 studies with 1009 patients. , 2015, Atherosclerosis.

[9]  V. Kamanna,et al.  Niacin inhibits fat accumulation, oxidative stress, and inflammatory cytokine IL-8 in cultured hepatocytes: Impact on non-alcoholic fatty liver disease. , 2015, Metabolism: clinical and experimental.

[10]  Ž. Reiner.  PCSK9 inhibitors – past, present and future , 2015, Expert opinion on drug metabolism & toxicology.

[11]  C. Borghi,et al.  Profile of evolocumab and its potential in the treatment of hyperlipidemia , 2015, Drug design, development and therapy.

[12]  K. Kalantar-Zadeh,et al.  Niacin and progression of CKD. , 2015, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[13]  W. Boden,et al.  Is HPS2-THRIVE the death knell for niacin? , 2015, Journal of clinical lipidology.

[14]  S. Yamashita,et al.  Effect of Extended-Release Niacin/Laropiprant Combination on Plasma Adiponectin and Insulin Resistance in Chinese Patients with Dyslipidaemia , 2015, Disease markers.

[15]  H. Bays,et al.  Extended-release niacin/laropiprant significantly improves lipid levels in type 2 diabetes mellitus irrespective of baseline glycemic control , 2015, Vascular health and risk management.

[16]  W. Masson,et al.  Abstract 13041: An Updated Meta-Analysis and Meta-Regression of Niacin in Cardiovascular Prevention , 2014 .

[17]  Y. Panahi,et al.  Lipid-modifying effects of adjunctive therapy with curcuminoids-piperine combination in patients with metabolic syndrome: results of a randomized controlled trial. , 2014, Complementary therapies in medicine.

[18]  Sarah Parish,et al.  Effects of extended-release niacin with laropiprant in high-risk patients. , 2014, The New England journal of medicine.

[19]  Jennifer G. Robinson,et al.  2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. , 2014, Circulation.

[20]  S. Lamon-Fava,et al.  Lipoprotein(a) metabolism , 2014, Current opinion in lipidology.

[21]  B. Jug,et al.  Extended-release niacin/laropiprant improves endothelial function in patients after myocardial infarction , 2014, Heart and Vessels.

[22]  R. Mateo-Gallego,et al.  Effect of Nicotinic acid/Laropiprant in the lipoprotein(a) concentration with regard to baseline lipoprotein(a) concentration and LPA genotype. , 2014, Metabolism: clinical and experimental.

[23]  Jennifer G. Robinson,et al.  Relationship of apolipoproteins A-1 and B, and lipoprotein(a) to cardiovascular outcomes: the AIM-HIGH trial (Atherothrombosis Intervention in Metabolic Syndrome with Low HDL/High Triglyceride and Impact on Global Health Outcomes). , 2013, Journal of the American College of Cardiology.

[24]  David C. Anderson,et al.  Extended-Release Niacin Therapy and Risk of Ischemic Stroke in Patients With Cardiovascular Disease: The Atherothrombosis Intervention in Metabolic Syndrome With Low HDL/High Triglycerides Impact on Global Health Outcome (AIM–HIGH) Trial , 2013, Stroke.

[25]  G. Watts,et al.  New Therapies Targeting apoB Metabolism for High-Risk Patients with Inherited Dyslipidaemias: What Can the Clinician Expect? , 2013, Cardiovascular Drugs and Therapy.

[26]  A. Sahebkar,et al.  New LDL-cholesterol lowering therapies: pharmacology, clinical trials, and relevance to acute coronary syndromes. , 2013, Clinical therapeutics.

[27]  J. Hoover-Plow,et al.  Lipoprotein(a) metabolism: potential sites for therapeutic targets. , 2013, Metabolism: clinical and experimental.

[28]  S. Tsimikas,et al.  Emerging therapeutic agents to lower lipoprotein (a) levels , 2012, Current opinion in lipidology.

[29]  K. Porter,et al.  Lipoprotein(a): Cellular Effects and Molecular Mechanisms , 2012, Cholesterol.

[30]  Shah Ebrahim,et al.  European Guidelines on Cardiovascular Disease Prevention in Clinical Practice (Version 2012) , 2012, International Journal of Behavioral Medicine.

[31]  Hae-Young Lee,et al.  Efficacy and tolerability of a new extended-release formulation of nicotinic acid in Korean adults with mixed dyslipidemia: an 8-week, multicenter, prospective, randomized, double-blind, and placebo-controlled trial. , 2011, Clinical therapeutics.

[32]  M. Taskinen,et al.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). , 2011, Atherosclerosis.

[33]  J. Borén,et al.  Lipoprotein(a) as a cardiovascular risk factor: current status , 2010, European heart journal.

[34]  Jiandie D. Lin,et al.  Regulation of hepatic ApoC3 expression by PGC-1β mediates hypolipidemic effect of nicotinic acid. , 2010, Cell metabolism.

[35]  Pierre Amarenco,et al.  Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis. , 2010, Atherosclerosis.

[36]  J. Paolini,et al.  Efficacy and safety of extended‐release niacin/laropiprant plus statin vs. doubling the dose of statin in patients with primary hypercholesterolaemia or mixed dyslipidaemia , 2010, International journal of clinical practice.

[37]  J. Danesh,et al.  Lipoprotein(a) concentration and the risk of coronary heart disease, stroke, and nonvascular mortality. , 2009, JAMA.

[38]  M. Reilly,et al.  Atheroprotective lipoprotein effects of a niacin-simvastatin combination compared to low- and high-dose simvastatin monotherapy. , 2009, American heart journal.

[39]  G. Utermann,et al.  Longitudinal cohort study on the effectiveness of lipid apheresis treatment to reduce high lipoprotein(a) levels and prevent major adverse coronary events , 2009, Nature Clinical Practice Cardiovascular Medicine.

[40]  A. Lichtenstein,et al.  Extended-Release Niacin Alters the Metabolism of Plasma Apolipoprotein (Apo) A-I and ApoB-Containing Lipoproteins , 2008, Arteriosclerosis, thrombosis, and vascular biology.

[41]  S. Offermanns,et al.  Nicotinic acid: pharmacological effects and mechanisms of action. , 2008, Annual review of pharmacology and toxicology.

[42]  Dennis A. Smith.  Commentary on variability in vitamin K antagonist metabolism , 2006, Expert opinion on drug metabolism & toxicology.

[43]  Jeannie K. Lee,et al.  Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: A Double-Blind, Placebo-Controlled Study of Extended-Release Niacin on Atherosclerosis Progression in Secondary Prevention Patients Treated With Statins , 2004, Circulation.

[44]  V. Kamanna,et al.  Niacin therapy in atherosclerosis. , 2004 .

[45]  H. Superko,et al.  Differential effect of two nicotinic acid preparations on low-density lipoprotein subclass distribution in patients classified as low-density lipoprotein pattern A, B, or I. , 2004, The American journal of cardiology.

[46]  P. Thompson,et al.  Efficacy of extended-release niacin with lovastatin for hypercholesterolemia: assessing all reasonable doses with innovative surface graph analysis. , 2004, Archives of internal medicine.

[47]  Shaista Malik,et al.  Niacin, lipids, and heart disease , 2003, Current cardiology reports.

[48]  R. Fogari,et al.  The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. , 2003, Clinical therapeutics.

[49]  K. Aihara,et al.  Effect of aspirin treatment on serum concentrations of lipoprotein(a) in patients with atherosclerotic diseases. , 2002, Clinical chemistry.

[50]  M. Charles,et al.  Extended-release niacin treatment of the atherogenic lipid profile and lipoprotein(a) in diabetes. , 2002, Metabolism: clinical and experimental.

[51]  S. Grundy,et al.  Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. , 2002, Archives of internal medicine.

[52]  E. Bolson,et al.  Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. , 2001, The New England journal of medicine.

[53]  C. Sirtori,et al.  L-carnitine reduces plasma lipoprotein(a) levels in patients with hyper Lp(a). , 2000, Nutrition, metabolism, and cardiovascular diseases : NMCD.

[54]  S Duval,et al.  Trim and Fill: A Simple Funnel‐Plot–Based Method of Testing and Adjusting for Publication Bias in Meta‐Analysis , 2000, Biometrics.

[55]  A. Goldberg,et al.  Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. , 2000, The American journal of cardiology.

[56]  D. Capuzzi,et al.  A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients. , 1998, The American journal of cardiology.

[57]  A. Goldberg,et al.  Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia. , 1998, Metabolism: clinical and experimental.

[58]  C. O'connor,et al.  Effectiveness of once-nightly dosing of extended-release niacin alone and in combination for hypercholesterolemia. , 1998, The American journal of cardiology.

[59]  R. Lanford,et al.  Cell surface assembly of lipoprotein(a) in primary cultures of baboon hepatocytes. , 1994, The Journal of biological chemistry.

[60]  P. Crosignani,et al.  The lowering of lipoprotein[a] induced by estrogen plus progesterone replacement therapy in postmenopausal women. , 1993, Archives of internal medicine.

[61]  F. Krempler,et al.  Lipoprotein (a) is not a metabolic product of other lipoproteins containing apolipoprotein B. , 1979, Biochimica et biophysica acta.

[62]  'Ten Commandments' from the 2016 ESC/EAS Guidelines for the management of dyslipidaemias. , 2016, European heart journal.

[63]  M. Pencina,et al.  Head-to-head comparison of statins versus fibrates in reducing plasma fibrinogen concentrations: A systematic review and meta-analysis. , 2016, Pharmacological research.

[64]  J. Tetzlaff,et al.  Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement , 2014 .

[65]  U. Julius,et al.  Nicotinic acid as a lipid-modifying drug--a review. , 2013, Atherosclerosis. Supplements.

[66]  P. P. Toth.  Niacin in Patients with Low HDL Cholesterol Levels Receiving Intensive Statin Therapy , 2012 .

[67]  C. Ballantyne,et al.  Efficacy and safety profile of co-administered ER niacin/laropiprant and simvastatin in dyslipidaemia , 2009 .

[68]  D. Moher,et al.  Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. , 2009, Journal of clinical epidemiology.

[69]  Karen Shashok,et al.  BMC Medical Research Methodology BioMed Central Debate Conducting a meta-ethnography of qualitative literature: Lessons learnt , 2008 .

[70]  S. Marcovina,et al.  Thematic Review Series: Lipoprotein (a): Coming of Age at Last Lipoprotein (a) measurements for clinical application , 2022 .